TABLE OF CONTENTS
1 EXECUTIVE SUMMARY
1.1 OVERVIEW
2 MARKET INTRODUCTION
2.1 SCOPE OF THE STUDY
2.2 RESEARCH OBJECTIVE
2.3 LIST OF ASSUMPTIONS
3 RESEARCH METHODOLOGY
3.1 OVERVIEW
3.2 DATA MINING
3.3 SECONDARY RESEARCH
3.4 PRIMARY RESEARCH
3.4.1 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS
3.4.2 BREAKDOWN OF PRIMARY RESPONDENTS
3.5 FORECASTING TECHNIQUES
3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION
3.6.1 BOTTOM-UP APPROACH
3.6.2 TOP-DOWN APPROACH
3.7 DATA TRIANGULATION
3.8 VALIDATION
4 MARKET DYNAMICS
4.1 OVERVIEW
4.2 DRIVERS
4.2.1 RISING PREFERENCE FOR PERSONALIZED MEDICINE
4.2.2 INCREASING COLLABORATION AMONG COMPANIES AND DRUG-DIAGNOSTIC CO-DEVELOPMENT
4.2.3 INCREASING PRODUCT APPROVAL BY MAJOR PLAYERS
4.3 RESTRAINTS
4.3.1 LACK OF REIMBURSEMENT IN DEVELOPING REGIONS
4.3.2 LIMITED ADOPTION OF CDX AND PRESENCE OF ALTERNATIVE THERAPIES
4.4 OPPORTUNITIES
4.4.1 EXPANSION INTO NEWER INDICATION AREAS
5 MARKET FACTOR ANALYSIS
5.1 SUPPLY CHAIN ANALYSIS
5.1.1 R&D AND DESIGNING
5.1.2 MANUFACTURING
5.1.3 DISTRIBUTION
5.1.4 MARKETING & SALES
5.1.5 POST-SALES MONITORING
5.2 PORTER'S FIVE FORCES MODEL
5.2.1 THREAT OF NEW ENTRANTS
5.2.2 BARGAINING POWER OF SUPPLIERS
5.2.3 THREAT OF SUBSTITUTES
5.2.4 BARGAINING POWER OF BUYERS
5.2.5 INTENSITY OF RIVALRY
5.3 IMPACT OF CORONAVIRUS (COVID)-19
6 GLOBAL COMPANION DIAGNOSTICS MARKET, BY PRODUCTS & SERVICES
6.1 OVERVIEW
6.2 ASSAYS, KITS, & REAGENTS
6.3 SOFTWARE & SERVICES
7 GLOBAL COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY
7.1 OVERVIEW
7.2 POLYMERASE CHAIN REACTION (PCR)
7.3 NEXT-GENERATION SEQUENCING (NGS)
7.4 IN SITU HYBRIDIZATION (ISH)
7.5 IMMUNOHISTOCHEMISTRY (IHC)
7.6 OTHERS
8 GLOBAL COMPANION DIAGNOSTICS MARKET, BY INDICATION
8.1 OVERVIEW
8.2 CANCER
8.2.1 LUNG CANCER
8.2.2 BREAST CANCER
8.2.3 COLORECTAL CANCER
8.2.4 GASTRIC CANCER
8.2.5 MELANOMA
8.2.6 OTHERS
8.3 NEUROLOGICAL DISEASES
8.4 INFECTIOUS DISEASES
8.5 CARDIOVASCULAR DISEASES
8.6 OTHERS
9 GLOBAL COMPANION DIAGNOSTICS MARKET, BY END USER
9.1 OVERVIEW
9.2 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES
9.3 CONTRACT RESEARCH ORGANIZATIONS
9.4 LABORATORIES
9.5 OTHERS
10 GLOBAL COMPANION DIAGNOSTICS MARKET, BY REGION
10.1 OVERVIEW
10.2 AMERICAS
10.2.1 NORTH AMERICA
10.2.1.1 US
10.2.1.2 CANADA
10.2.2 LATIN AMERICA
10.3 EUROPE
10.3.1 WESTERN EUROPE
10.3.1.1 GERMANY
10.3.1.2 FRANCE
10.3.1.3 UK
10.3.1.4 ITALY
10.3.1.5 SPAIN
10.3.1.6 REST OF WESTERN EUROPE
10.3.2 EASTERN EUROPE
10.4 ASIA-PACIFIC
10.4.1 CHINA
10.4.2 JAPAN
10.4.3 INDIA
10.4.4 AUSTRALIA
10.4.5 SOUTH KOREA
10.4.6 REST OF ASIA-PACIFIC
10.5 MIDDLE EAST & AFRICA
10.5.1 MIDDLE EAST
10.5.2 AFRICA
11 COMPETITIVE LANDSCAPE
11.1 OVERVIEW
11.2 COMPETITIVE BENCHMARKING
11.3 MAJOR GROWTH STRATEGY IN COMPANION DIAGNOSTIC MARKET
11.4 THE LEADING PLAYER IN TERMS OF NUMBER OF DEVELOPMENTS IN THE COMPANION DIAGNOSTIC MARKET
11.5 KEY DEVELOPMENT ANALYSIS
11.6 KEY DEVELOPMENTS & GROWTH STRATEGIES
11.6.1 PRODUCT APPROVALS AND PRODUCT LAUNCHES
11.6.2 PARTNERSHIP/COLLABORATION
11.6.3 EXPANSIONS/AGREEMENT
11.6.4 MERGERS & ACQUISITIONS
11.7 MAJOR PLAYERS SALES ANALYSIS
11.7.1 SALES & OPERATING INCOME
11.8 MAJOR PLAYERS R&D ANALYSIS
12 COMPANY PROFILES
12.1 F. HOFFMANN-LA ROCHE LTD
12.1.1 COMPANY OVERVIEW
12.1.2 FINANCIAL OVERVIEW
12.1.3 PRODUCTS/SERVICES/SOLUTIONS OFFERED
12.1.4 KEY DEVELOPMENTS
12.1.5 SWOT ANALYSIS
12.1.6 KEY STRATEGIES
12.2 THERMO FISHER SCIENTIFIC INC.
12.2.1 COMPANY OVERVIEW
12.2.2 FINANCIAL OVERVIEW
12.2.3 PRODUCTS/SERVICES/SOLUTIONS OFFERED
12.2.4 KEY DEVELOPMENTS
12.2.5 SWOT ANALYSIS
12.2.6 KEY STRATEGIES
12.3 AGILENT TECHNOLOGIES, INC.
12.3.1 COMPANY OVERVIEW
12.3.2 FINANCIAL OVERVIEW
12.3.3 PRODUCTS/SERVICES/SOLUTIONS OFFERED
12.3.4 KEY DEVELOPMENTS
12.3.5 SWOT ANALYSIS
12.3.6 KEY STRATEGIES
12.4 QIAGEN
12.4.1 COMPANY OVERVIEW
12.4.2 FINANCIAL OVERVIEW
12.4.3 PRODUCTS/SERVICES OFFERED
12.4.4 KEY DEVELOPMENTS
12.4.5 SWOT ANALYSIS
12.4.6 KEY STRATEGIES
12.5 ABBOTT
12.5.1 COMPANY OVERVIEW
12.5.2 FINANCIAL OVERVIEW
12.5.3 PRODUCTS/SERVICES/SOLUTIONS OFFERED
12.5.4 KEY DEVELOPMENTS
12.5.5 KEY STRATEGIES
12.6 BIOMÉRIEUX SA
12.6.1 COMPANY OVERVIEW
12.6.2 FINANCIAL OVERVIEW
12.6.3 PRODUCTS/SERVICES/SOLUTIONS OFFERED
12.6.4 KEY DEVELOPMENTS
12.6.5 KEY STRATEGIES
12.7 LEICA BIOSYSTEMS NUSSLOCH GMBH
12.7.1 COMPANY OVERVIEW
12.7.2 FINANCIAL OVERVIEW
12.7.3 PRODUCTS/SERVICES/SOLUTIONS OFFERED
12.7.4 KEY DEVELOPMENTS
12.7.5 KEY STRATEGIES
12.8 ILLUMINA, INC.
12.8.1 COMPANY OVERVIEW
12.8.2 FINANCIAL OVERVIEW
12.8.3 PRODUCTS/SERVICES/SOLUTIONS OFFERED
12.8.4 KEY DEVELOPMENTS
12.8.5 KEY STRATEGIES
12.9 MYRIAD GENETICS, INC
12.9.1 COMPANY OVERVIEW
12.9.2 FINANCIAL OVERVIEW
12.9.3 PRODUCTS/SERVICES/SOLUTIONS OFFERED
12.9.4 KEY DEVELOPMENTS
12.9.5 SWOT ANALYSIS
12.9.6 KEY STRATEGIES
12.10 ARCHERDX, INC.
12.10.1 COMPANY OVERVIEW
12.10.2 FINANCIAL OVERVIEW
12.10.3 PRODUCTS/SERVICES/SOLUTIONS OFFERED
12.10.4 KEY DEVELOPMENTS
12.10.5 KEY STRATEGIES
12.11 FOUNDATION MEDICINE, INC.
12.11.1 COMPANY OVERVIEW
12.11.2 FINANCIAL OVERVIEW
12.11.3 PRODUCTS/SERVICES/SOLUTIONS OFFERED
12.11.4 KEY DEVELOPMENTS
12.11.5 KEY STRATEGIES
12.12 NG BIOTECH
12.12.1 COMPANY OVERVIEW
12.12.2 FINANCIAL OVERVIEW
12.12.3 PRODUCTS/SERVICES/SOLUTIONS OFFERED
12.12.4 KEY DEVELOPMENTS
12.12.5 KEY STRATEGIES
12.13 ICON PLC
12.13.1 COMPANY OVERVIEW
12.13.2 FINANCIAL OVERVIEW
12.13.3 PRODUCTS/SERVICES/SOLUTIONS OFFERED
12.13.4 KEY DEVELOPMENTS
12.13.5 KEY STRATEGIES
12.14 INVIVOSCRIBE, INC.
12.14.1 COMPANY OVERVIEW
12.14.2 FINANCIAL OVERVIEW
12.14.3 PRODUCTS/SERVICES/SOLUTIONS OFFERED
12.14.4 KEY DEVELOPMENTS
12.14.5 KEY STRATEGIES
12.15 ABNOVA CORPORATION
12.15.1 COMPANY OVERVIEW
12.15.2 FINANCIAL OVERVIEW
12.15.3 PRODUCTS/SERVICES/SOLUTIONS OFFERED
12.15.4 KEY DEVELOPMENTS
12.15.5 KEY STRATEGIES
12.16 GUARDANT HEALTH
12.16.1 COMPANY OVERVIEW
12.16.2 FINANCIAL OVERVIEW
12.16.3 PRODUCTS/SERVICES/SOLUTIONS OFFERED
12.16.4 KEY DEVELOPMENTS
12.16.5 KEY STRATEGIES
13 APPENDIX
13.1 REFERENCES
13.2 RELATED REPORTS
LIST OF TABLES
TABLE 1 LIST OF ASSUMPTIONS & LIMITATIONS
TABLE 2 GLOBAL COMPANION DIAGNOSTICS MARKET, BY PRODUCTS & SERVICES, 2018-2030 (USD MILLION)
TABLE 3 GLOBAL COMPANION DIAGNOSTICS MARKET, FOR ASSAYS, KITS, & REAGENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 4 GLOBAL COMPANION DIAGNOSTICS MARKET, FOR SOFTWARE & SERVICES, BY REGION, 2018-2030 (USD MILLION)
TABLE 5 GLOBAL COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 6 GLOBAL COMPANION DIAGNOSTICS MARKET, FOR POLYMERASE CHAIN REACTION (PCR), BY REGION, 2018-2030 (USD MILLION)
TABLE 7 GLOBAL COMPANION DIAGNOSTICS MARKET, FOR NEXT-GENERATION SEQUENCING (NGS), BY REGION, 2018-2030 (USD MILLION)
TABLE 8 GLOBAL COMPANION DIAGNOSTICS MARKET, FOR IN SITU HYBRIDIZATION (ISH), BY REGION, 2018-2030 (USD MILLION)
TABLE 9 GLOBAL COMPANION DIAGNOSTICS MARKET, FOR IMMUNOHISTOCHEMISTRY (IHC), BY REGION, 2018-2030 (USD MILLION)
TABLE 10 GLOBAL COMPANION DIAGNOSTICS MARKET, FOR OTHER TECHNOLOGIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 11 GLOBAL COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 12 GLOBAL COMPANION DIAGNOSTICS MARKET, FOR CANCER, BY TYPE, 2018-2030 (USD MILLION)
TABLE 13 GLOBAL COMPANION DIAGNOSTICS MARKET, FOR CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 14 GLOBAL COMPANION DIAGNOSTICS MARKET, FOR LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 15 GLOBAL COMPANION DIAGNOSTICS MARKET, FOR BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 16 GLOBAL COMPANION DIAGNOSTICS MARKET, FOR COLORECTAL CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 17 GLOBAL COMPANION DIAGNOSTICS MARKET, FOR GASTRIC CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 18 GLOBAL COMPANION DIAGNOSTICS MARKET, FOR MELANOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 19 GLOBAL COMPANION DIAGNOSTICS MARKET, FOR OTHER CANCERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 20 GLOBAL COMPANION DIAGNOSTICS MARKET, FOR NEUROLOGICAL DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 21 GLOBAL COMPANION DIAGNOSTICS MARKET, FOR INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 22 GLOBAL COMPANION DIAGNOSTICS MARKET, FOR CARDIOVASCULAR DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 23 GLOBAL COMPANION DIAGNOSTICS MARKET, FOR OTHER DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 24 GLOBAL COMPANION DIAGNOSTICS MARKET, BY END USER, 2018-2030 (USD MILLION)
TABLE 25 GLOBAL COMPANION DIAGNOSTICS MARKET, FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 26 GLOBAL COMPANION DIAGNOSTICS MARKET, FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 27 GLOBAL COMPANION DIAGNOSTICS MARKET, FOR LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 28 GLOBAL COMPANION DIAGNOSTICS MARKET, FOR OTHER END USERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 29 GLOBAL: COMPANION DIAGNOSTICS MARKET, BY REGION, 2018-2030 (USD MILLION)
TABLE 30 AMERICAS: COMPANION DIAGNOSTICS MARKET, BY REGION, 2018-2030 (USD MILLION)
TABLE 31 AMERICAS: COMPANION DIAGNOSTICS MARKET, BY PRODUCTS & SERVICES, 2018-2030 (USD MILLION)
TABLE 32 AMERICAS: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 33 AMERICAS: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 34 AMERICAS: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2018-2030 (USD MILLION)
TABLE 35 AMERICAS: COMPANION DIAGNOSTICS MARKET, BY END USER, 2018-2030 (USD MILLION)
TABLE 36 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 37 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY PRODUCTS & SERVICES, 2018-2030 (USD MILLION)
TABLE 38 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 39 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 40 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2018-2030 (USD MILLION)
TABLE 41 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2018-2030 (USD MILLION)
TABLE 42 US: COMPANION DIAGNOSTICS MARKET, BY PRODUCTS & SERVICES, 2018-2030 (USD MILLION)
TABLE 43 US: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 44 US: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 45 US: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2018-2030 (USD MILLION)
TABLE 46 US: COMPANION DIAGNOSTICS MARKET, BY END USER, 2018-2030 (USD MILLION)
TABLE 47 CANADA: COMPANION DIAGNOSTICS MARKET, BY PRODUCTS & SERVICES, 2018-2030 (USD MILLION)
TABLE 48 CANADA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 49 CANADA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 50 CANADA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2018-2030 (USD MILLION)
TABLE 51 CANADA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2018-2030 (USD MILLION)
TABLE 52 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY PRODUCTS & SERVICES, 2018-2030 (USD MILLION)
TABLE 53 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 54 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 55 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2018-2030 (USD MILLION)
TABLE 56 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2018-2030 (USD MILLION)
TABLE 57 EUROPE: COMPANION DIAGNOSTICS MARKET, BY REGION, 2018-2030 (USD MILLION)
TABLE 58 EUROPE: COMPANION DIAGNOSTICS MARKET, BY PRODUCTS & SERVICES, 2018–2030 (USD MILLION)
TABLE 59 EUROPE: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018–2030 (USD MILLION)
TABLE 60 EUROPE: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2018–2030 (USD MILLION)
TABLE 61 EUROPE: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2018–2030 (USD MILLION)
TABLE 62 EUROPE: COMPANION DIAGNOSTICS MARKET, BY END USER, 2018–2030 (USD MILLION)
TABLE 63 WESTERN EUROPE: COMPANION DIAGNOSTICS MARKET, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 64 WESTERN EUROPE: COMPANION DIAGNOSTICS MARKET, BY PRODUCTS & SERVICES, 2018–2030 (USD MILLION)
TABLE 65 WESTERN EUROPE: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018–2030 (USD MILLION)
TABLE 66 WESTERN EUROPE: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2018–2030 (USD MILLION)
TABLE 67 WESTERN EUROPE: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2018–2030 (USD MILLION)
TABLE 68 WESTERN EUROPE: COMPANION DIAGNOSTICS MARKET, BY END USER, 2018–2030 (USD MILLION)
TABLE 69 GERMANY: COMPANION DIAGNOSTICS MARKET, BY PRODUCTS & SERVICES, 2018–2030 (USD MILLION)
